Eupraxia Pharmaceuticals reports Q1 results

May 05, 2022 5:54 PM ETEupraxia Pharmaceuticals Inc. (EPRXF), EPRX:CABy: Meghavi Singh, SA News Editor
  • Eupraxia Pharmaceuticals press release (OTCPK:EPRXF): Q1 net loss of $3.8 million for the three months ended March 31, 2022, versus $8.9 million for the quarter ended March 31, 2021.
  • The Company had a cash and short-term investments balance of $25.9 million as at March 31, 2022.
  • Management believes it has sufficient resources to fund the Company through to the fourth quarter of 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.